BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1617625)

  • 1. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
    Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
    Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipyridamole enhancement of etoposide sensitivity.
    Howell SB; Hom DK; Sanga R; Vick JS; Chan TC
    Cancer Res; 1989 Aug; 49(15):4147-53. PubMed ID: 2545335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
    Marverti G; Andrews PA
    Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
    Jekunen AP; Christen RD; Shalinsky DR; Howell SB
    Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro.
    Shalinsky DR; Andreeff M; Howell SB
    Cancer Res; 1990 Dec; 50(23):7537-43. PubMed ID: 1979245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
    Holzer AK; Katano K; Klomp LW; Howell SB
    Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
    Jekunen AP; Shalinsky DR; Hom DK; Albright KD; Heath D; Howell SB
    Biochem Pharmacol; 1993 May; 45(10):2079-85. PubMed ID: 8512589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
    Howell SB; Hom D; Sanga R; Vick JS; Abramson IS
    Cancer Res; 1989 Jun; 49(12):3178-83. PubMed ID: 2720673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
    Andrews PA; Albright KD
    Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-PĂ©otti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cisplatin resistance in human malignant melanoma cells.
    McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
    Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
    Melvik JE; Pettersen EO
    Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
    Chen G; Zeller WJ
    Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin.
    Cemazar M; Sersa G; Miklavcic D
    Anticancer Res; 1998; 18(6A):4463-6. PubMed ID: 9891510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.